Navigation Links
Mayo Clinic finds withdrawing ventricular assist device support ethical
Date:8/2/2010

ROCHESTER, Minn. - Patients have the right to refuse or request the withdrawal of any unwanted treatment. In an article published in the online issue of Mayo Clinic Proceedings, investigators explore the legal and ethical permissibility of carrying out such a request specific to a ventricular assist device (VAD).

The left-VAD (LVAD) is a new technology that provides circulatory support for patients with severe heart failure who are awaiting a heart transplant. This technology also can serve as a long-term treatment option for patients who are not candidates for heart transplant, but still need circulatory support, also known as "destination therapy."

Notably, VAD technology is continuously improving. "A recent trial demonstrated significantly greater two-year survival among patients with severe heart failure treated with continuous-flow LVADs than among patients treated with older pulsatile-flow devices (58 percent versus 24 percent)," says Paul Mueller, M.D., lead investigator, Mayo Clinic Department of General Internal Medicine. At Mayo Clinic the two-year survival rate for patients treated with LVAD is 74 percent. Therefore, the VAD is a long-term treatment for patients with severe heart failure.

Nevertheless, some patients treated with VADs experience complications (e.g., stroke) related to their treatment or their underlying disease and request withdrawal of VAD support.

Dr. Mueller and colleagues describe 14 patients who requested (or their surrogates requested) withdrawal of LVAD support and these requests were carried out by their physicians. Dr. Mueller and colleagues then describe the ethical and legal permissibility of carrying out such requests.

"If the patient (or their surrogate) concludes that VAD support is more burdensome than beneficial, they may request withdrawal of VAD support (that is, that the device be turned off)," says Dr. Mueller. "Assuming the patient (or surrogate) is informed regarding alternatives to and consequences of withdrawing VAD support, clinicians should carry out such requests or transfer the patient's care to another physician. The cause of death in these cases is the underlying heart disease, not assisted suicide or euthanasia. In our view, carrying out such requests is permissible in accordance with the principles that apply to withdrawing other life-sustaining treatments." Examples are hemodialysis, mechanical ventilation and artificial hydration and nutrition.


'/>"/>

Contact: Rebecca Finseth
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Clinical trials can be improved by managing the learning curve
2. Mayo Clinic Center for Innovation to sponsor a collaborative symposium on innovations in health care experience and delivery
3. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
4. UC San Diego receives major clinical and translational science award
5. Hopkins faculty lead development of report to FDA on ethical, scientific issues related to post-market clinical trials
6. Mayo Clinic Proceedings: Sexual abuse survivors have increased of psychiatric disorders
7. Mayo Clinic study finds apathy and depression predict progression from mild cognitive impairment
8. Pediatric clinical studies appear prone to bias, Hopkins review shows
9. St. Elizabeth Dental Clinic Named one of the Best in the Nation
10. Electronic health records prime clinicians to provide progressive care to older adults
11. CELLING Treatment Centers New Clinic Revolutionizes Spinal Care with Adult Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
(Date:8/16/2017)... ... , ... “God Will Break Every Chain”: an inspirational story for those shackled by the chains ... author, Evangelist Joann Shivers, a writer and a woman of great faith and wisdom. ... early age. She was born and raised in Vero Beach, Florida and has dedicated ...
(Date:8/15/2017)... ... August 15, 2017 , ... The first study to ... multiple myeloma has been completed, with the team’s findings now published online ahead of ... , Director of the Blood and Marrow Transplant Program at Roswell Park Cancer Institute, ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading ... on the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The ... area who has shown three consecutive years of growth. For this year’s award, Progressive ...
(Date:8/15/2017)... ... August 15, 2017 , ... Dr. Timothy Davis ... periodontal disease . This information can be used to develop patient-specific treatment ... The two salivary diagnostic tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® ...
Breaking Medicine News(10 mins):
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
(Date:7/27/2017)... Pa., July 27, 2017  West Pharmaceutical Services, Inc. ... results for the second-quarter 2017 and updated financial guidance ... Second-Quarter 2017 Highlights Reported net ... over the prior-year quarter. Net sales at constant currency ... reported-diluted EPS was $0.51, compared to $0.60 in the ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: